According to the results obtained by Rieck et al., a haplotype (TTCTA) derived from rs2283265 polymorphism in the DRD2 gene region is associated with dyskinesia during levodopa treatment, which results from the reduced expression of the DRD2 gene (Rieck et al. 2012). The gene discussed is DRD2; the disease is drug-induced dyskinesia.